{
  "docId": "019dd923-622c-750b-8b9b-905be5d022fb",
  "docSlug": "0c95c1ec255f",
  "documentTitle": "Pershing Square Portfolio (multiple positions)",
  "authorId": "01_Pershing_Square",
  "authorName": "Pershing Square",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2015-04-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 18,
  "pageCount": 67,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_takeaways",
  "function": "illustrate_case",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The chart uses a timeline-based annotation approach to correlate stock performance with corporate M&A activity.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/18",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "callout",
      "text": "An investment in Valeant shares on the day Mike Pearson became CEO has appreciated to 42x its initial value in seven years including dividend reinvestment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfaf5c26-f205-488b-9886-a0efd8a7603e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Valeant total shareholder return from 2/1/2008 to 4/22/2015",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4e61074-03cd-4650-b9cf-fdda6575fe30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Total Shareholder Return: 4,177%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-70f4-766c-b4d7-e759cdb6d7d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: Chart shows the total shareholder return with the initial share price indexed to 100% for an investment in Valeant Pharmaceuticals International...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cbcd392-bbe6-4916-8196-fcb3e275802e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Valeant's Total Shareholder Return Since Pearson's CEO Appointment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5eaa4a5d-ceba-4e32-9e1d-4672bf9b7e7c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "79990321-edb1-4e55-aceb-f2bd9eb93f0a",
      "evidence": "Valeant's Total Shareholder Return Since Pearson's CEO Appointment shows a chart with a clear before and after framing.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "1d296e11-5021-4834-9cfc-cc613e84c22b",
      "evidence": "Chronological mapping of stock performance against M&A events",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "ac9280a9-0063-463b-aaa0-8772c74c91e1",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Early Struggles",
      "beatSlug": "rags-to-riches-early-struggles",
      "evidence": "Discussion of challenges faced by portfolio companies.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 13,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "db62f30e-643d-48df-9336-aed60ac28d9e",
      "evidence": "Multiple 'before-after' slides illustrating share price growth.",
      "position": 0,
      "objective": "Show Allergan's and Valeant's share price performance",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.8,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}